[Longterm therapy and etofibrate (author's transl)].
The stabilization parameters of patients under routine care are differentiated. 20 hyperlipoproteinemic patients (types IIa, IIb and IV) who were difficult to stabilize were treated with 0.9 g etofibrate daily. In addition to the cholesterold and triglyceride levels, we followed up the laboratory control parameters in the serum, fasting blood sugar and differential blood count. During the treatment period the cholesterol levels fell to 18%, triglycerides to 50%. Tachyphylaxis was never seen. The good tolerance of etofibrate shows that the substance is suitable as a potent hypolipidemic agent for longterm treatment of hyperlipoproteinemia.
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001772:Blood Cell Count; D001786:Blood Glucose / Q000032:analysis; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D006801:Humans; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D001786:Blood Glucose; D014280:Triglycerides; C009746:etofibrate; D002995:Clofibric Acid; D002994:Clofibrate
Langzeittherapie mit Etofibrat.